Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning
- PMID: 16808549
- DOI: 10.2165/00002018-200629070-00002
Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning
Abstract
In the process of conceiving a pharmacovigilance plan, as proposed in the International Conference on Harmonisation E2E guideline, the challenge will be how to address possible safety issues with a set of appropriate pharmacovigilance methods. For successful planning, the various and sometimes complex dimensions of the adverse drug reaction in question have to be appropriately described. In order to accommodate these better, a 3-dimensional approach, based on dose, time and patient susceptibility, has recently been proposed (the DoTS model). This approach offers a way of presenting the various dimensions of the problem graphically. The aim of this article is to propose how an extended DoTS model, applied to three different scenarios, could give a better understanding of adverse drug reactions and assist in preparing a pharmacovigilance plan.
Similar articles
-
Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.Drug Saf. 2006;29(8):657-73. doi: 10.2165/00002018-200629080-00003. Drug Saf. 2006. PMID: 16872240 Review.
-
International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.Fed Regist. 2005 Apr 1;70(62):16827-8. Fed Regist. 2005. PMID: 15803631
-
Pharmacoepidemiology and its input to pharmacovigilance.Therapie. 2016 Apr;71(2):211-6. doi: 10.1016/j.therap.2016.02.016. Epub 2016 Feb 6. Therapie. 2016. PMID: 27080840 English, French.
-
Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):377-87. doi: 10.1002/pds.1043. Pharmacoepidemiol Drug Saf. 2005. PMID: 15517542
-
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.Joint Bone Spine. 2006 Dec;73(6):629-32. doi: 10.1016/j.jbspin.2006.09.002. Epub 2006 Oct 12. Joint Bone Spine. 2006. PMID: 17110152 Review. No abstract available.
Cited by
-
EIDOS: a mechanistic classification of adverse drug effects.Drug Saf. 2010 Jan 1;33(1):15-23. doi: 10.2165/11318910-000000000-00000. Drug Saf. 2010. PMID: 20000863
-
The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy.Sci Rep. 2020 Jun 12;10(1):9552. doi: 10.1038/s41598-020-66611-8. Sci Rep. 2020. PMID: 32533040 Free PMC article.
-
Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.J Food Drug Anal. 2018 Apr;26(2S):S3-S11. doi: 10.1016/j.jfda.2017.11.012. Epub 2018 Jan 17. J Food Drug Anal. 2018. PMID: 29703384 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical